adamantane has been researched along with Dyslipidemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarsson, M; Bhatt, DL; Cahn, A; Hirshberg, B; Hoekstra, JB; Im, K; Leiter, LA; Mosenzon, O; Raz, I; Scirica, BM; Stahre, CA; Teoh, H | 1 |
| Abdel-Rahman, SZ; El-Mesallamy, HO; Hamdy, NM; Mostafa, AM | 1 |
1 trial(s) available for adamantane and Dyslipidemia
| Article | Year |
|---|---|
Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.
Topics: Adamantane; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Mortality; Neoplasms; Risk Factors; Sex Factors; Smoking | 2016 |
1 other study(ies) available for adamantane and Dyslipidemia
| Article | Year |
|---|---|
Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes.
Topics: 3T3-L1 Cells; Adamantane; Adipocytes; Animals; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Cholesterol; Cholesterol, HDL; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Liver X Receptors; Mice; Nitriles; Pravastatin; Pyrrolidines; Vildagliptin | 2016 |